CSF Biomarkers as Indicators of Disease Severity in Probable Cerebral Amyloid Angiopathy: Insights Beyond MRI

MedXY Editorial Team•Sep 6, 2026•Neurology

In patients with probable cerebral amyloid angiopathy (CAA), lower cerebrospinal fluid (CSF) levels of β-amyloid 1-40 (Aβ40) and β-amyloid 1-42 (Aβ42) correlate with key MRI markers of disease severity, including cortical superficial siderosis and white matter hyperintensities.
CSF tau proteins (total tau and phosphorylated tau) showed no significant association with MRI markers, indicating these may not reflect vascular amyloid pathology in CAA.
Associations between CSF β-amyloid levels and MRI markers persisted regardless of clinical presentation or concomitant Alzheimer-like CSF profiles, suggesting CSF Aβ reflects vascular amyloid burden rather than downstream neurodegeneration.
These findings highlight CSF biomarkers’ potential role in assessing disease severity, with implications for prognosis and therapeutic monitoring in CAA.

MedXY registered readers

Sign in free to continue reading

Create or use your MedXY account to unlock the complete article.

This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.

In patients with probable cerebral amyloid angiopathy (CAA), lower cerebrospinal fluid (CSF) levels of β-amyloid 1-40 (Aβ40) and β-amyloid 1-42 (Aβ42) correlate with key MRI markers of disease severity, including cortical superficial siderosis and white matter hyperintensities.
CSF tau proteins (total tau and phosphorylated tau) showed no significant association with MRI markers, indicating these may not reflect vascular amyloid pathology in CAA.
Associations between CSF β-amyloid levels and MRI markers persisted regardless of clinical presentation or concomitant Alzheimer-like CSF profiles, suggesting CSF Aβ reflects vascular amyloid burden rather than downstream neurodegeneration.
These findings highlight CSF biomarkers’ potential role in assessing disease severity, with implications for prognosis and therapeutic monitoring in CAA.